Literature DB >> 6372686

Ceftazidime in the treatment of pediatric patients with severe urinary tract infections due to Pseudomonas spp.

F Rusconi, B M Assael, A Florioli, G Zaffaroni.   

Abstract

Fifteen pediatric patients with complicated urinary tract infections due to Pseudomonas spp. were treated for 10 to 18.5 days with ceftazidime administered intramuscularly twice daily. Urine sterilization during therapy was obtained in all patients. Three patients had relapses which were cured with a second course of ceftazidime. Minor liver damage, eosinophilia, and Candida superinfection developed in one patient each.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6372686      PMCID： PMC185530          DOI： 10.1128/AAC.25.3.395

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  THE LOCALIZATION AND TREATMENT OF URINARY TRACT INFECTIONS: THE ROLE OF BACTERICIDAL URINE LEVELS AS OPPOSED TO SERUM LEVELS.

Authors:  T A STAMEY; D E GOVAN; J M PALMER
Journal:  Medicine (Baltimore)       Date:  1965-01       Impact factor: 1.889

2.  Asymptomatic and symptomatic urinary tract infection in infancy.

Authors:  S R Siegel; B Sokoloff; B Siegel
Journal:  Am J Dis Child       Date:  1973-01

3.  Abnormal serum transaminase levels after parenteral ampicillin and carbenicillin administration.

Authors:  A K Knirsch; E J Gralla
Journal:  N Engl J Med       Date:  1970-05-07       Impact factor: 91.245

4.  Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections.

Authors:  N Clumeck; B Gordts; I Dab; N Jaspar; Y Van Laethem; J P Butzler
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

5.  Ceftazidime--a new extended-spectrum cephalosporin.

Authors:  D I Gozzard; A M Geddes; I D Farrell; S J Eykyn; I Phillips; R Wise; R M Brown
Journal:  Lancet       Date:  1982-05-22       Impact factor: 79.321

6.  Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

7.  Pharmacokinetics and safety of cefamandole in infants and children.

Authors:  C T Chang; A J Khan; M M Agbayani; R Jhaveri; I Amin; H E Evans
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

8.  Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis.

Authors:  R Padoan; A Brienza; R M Crossignani; G Lodi; A Giunta; B M Assael; F Granata; E Passarella; P A Vallaperta; L Xerri
Journal:  J Pediatr       Date:  1983-08       Impact factor: 4.406

9.  Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191
  9 in total
  4 in total

1.  Aztreonam in the treatment of severe urinary tract infections in pediatric patients.

Authors:  F Rusconi; B M Assael; A Boccazzi; R Colombo; R M Crossignani; L Garlaschi; L Rancilio
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 2.  [Ceftazidime in the treatment of pediatric infections--a review].

Authors:  D Adam; R Tolxdorff-Neutzling
Journal:  Infection       Date:  1987       Impact factor: 3.553

3.  Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia.

Authors:  J C Engle; P W Lifland; C J Schleupner
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 4.  Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.